Current trends in immunosuppression in pediatric orthotopic liver transplantation

George W Burke, D. Ranjan, M. Jonas, N. Koleilat, J. Miller

Research output: Contribution to journalArticle

Abstract

The availability of new immunosuppressive drugs during the last decade has fostered explosive growth in the field of transplantation. Specifically, the arrival of cyclosporine A and OKT3 has allowed the performance of liver transplantation in the pediatric population with one year survival rates of approximately 70%. Azathioprine and steroids are still used with cyclosporine A as part of triple immunosuppressive therapy. Each drug has its own array of side effects, although the triple regimen permits minimizing the dose (and hence the toxicity) of any single agent. Future directions for improvements in immunosuppression will include: 1) new drugs such a FK506 (which is currently undergoing a clinical trial in Pittsburg); and 2) the development of monoclonal antibodies to specific immune markers. These and other approaches may allow the development of transplant tolerance, ultimately rendering lifelong immunosuppression unnecessary.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
JournalInternational Pediatrics
Volume5
Issue number1
StatePublished - Oct 3 1990

Fingerprint

Liver Transplantation
Immunosuppression
Immunosuppressive Agents
Pediatrics
Cyclosporine
Pharmaceutical Preparations
Muromonab-CD3
Azathioprine
Tacrolimus
Transplantation
Biomarkers
Steroids
Monoclonal Antibodies
Clinical Trials
Transplants
Growth
Population
Therapeutics
Direction compound

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Current trends in immunosuppression in pediatric orthotopic liver transplantation. / Burke, George W; Ranjan, D.; Jonas, M.; Koleilat, N.; Miller, J.

In: International Pediatrics, Vol. 5, No. 1, 03.10.1990, p. 18-22.

Research output: Contribution to journalArticle

Burke, GW, Ranjan, D, Jonas, M, Koleilat, N & Miller, J 1990, 'Current trends in immunosuppression in pediatric orthotopic liver transplantation', International Pediatrics, vol. 5, no. 1, pp. 18-22.
Burke, George W ; Ranjan, D. ; Jonas, M. ; Koleilat, N. ; Miller, J. / Current trends in immunosuppression in pediatric orthotopic liver transplantation. In: International Pediatrics. 1990 ; Vol. 5, No. 1. pp. 18-22.
@article{f86adc5380dd4a6d934841a3b8e93e77,
title = "Current trends in immunosuppression in pediatric orthotopic liver transplantation",
abstract = "The availability of new immunosuppressive drugs during the last decade has fostered explosive growth in the field of transplantation. Specifically, the arrival of cyclosporine A and OKT3 has allowed the performance of liver transplantation in the pediatric population with one year survival rates of approximately 70{\%}. Azathioprine and steroids are still used with cyclosporine A as part of triple immunosuppressive therapy. Each drug has its own array of side effects, although the triple regimen permits minimizing the dose (and hence the toxicity) of any single agent. Future directions for improvements in immunosuppression will include: 1) new drugs such a FK506 (which is currently undergoing a clinical trial in Pittsburg); and 2) the development of monoclonal antibodies to specific immune markers. These and other approaches may allow the development of transplant tolerance, ultimately rendering lifelong immunosuppression unnecessary.",
author = "Burke, {George W} and D. Ranjan and M. Jonas and N. Koleilat and J. Miller",
year = "1990",
month = "10",
day = "3",
language = "English",
volume = "5",
pages = "18--22",
journal = "International Pediatrics",
issn = "0885-6265",
publisher = "Miami Children's Hospital Medical Journal Inc.",
number = "1",

}

TY - JOUR

T1 - Current trends in immunosuppression in pediatric orthotopic liver transplantation

AU - Burke, George W

AU - Ranjan, D.

AU - Jonas, M.

AU - Koleilat, N.

AU - Miller, J.

PY - 1990/10/3

Y1 - 1990/10/3

N2 - The availability of new immunosuppressive drugs during the last decade has fostered explosive growth in the field of transplantation. Specifically, the arrival of cyclosporine A and OKT3 has allowed the performance of liver transplantation in the pediatric population with one year survival rates of approximately 70%. Azathioprine and steroids are still used with cyclosporine A as part of triple immunosuppressive therapy. Each drug has its own array of side effects, although the triple regimen permits minimizing the dose (and hence the toxicity) of any single agent. Future directions for improvements in immunosuppression will include: 1) new drugs such a FK506 (which is currently undergoing a clinical trial in Pittsburg); and 2) the development of monoclonal antibodies to specific immune markers. These and other approaches may allow the development of transplant tolerance, ultimately rendering lifelong immunosuppression unnecessary.

AB - The availability of new immunosuppressive drugs during the last decade has fostered explosive growth in the field of transplantation. Specifically, the arrival of cyclosporine A and OKT3 has allowed the performance of liver transplantation in the pediatric population with one year survival rates of approximately 70%. Azathioprine and steroids are still used with cyclosporine A as part of triple immunosuppressive therapy. Each drug has its own array of side effects, although the triple regimen permits minimizing the dose (and hence the toxicity) of any single agent. Future directions for improvements in immunosuppression will include: 1) new drugs such a FK506 (which is currently undergoing a clinical trial in Pittsburg); and 2) the development of monoclonal antibodies to specific immune markers. These and other approaches may allow the development of transplant tolerance, ultimately rendering lifelong immunosuppression unnecessary.

UR - http://www.scopus.com/inward/record.url?scp=0025185608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025185608&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025185608

VL - 5

SP - 18

EP - 22

JO - International Pediatrics

JF - International Pediatrics

SN - 0885-6265

IS - 1

ER -